Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## **China Resources Pharmaceutical Group Limited**

(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

## **ANNOUNCEMENT**

## UNAUDITED FINANCIAL RESULTS OF JIANGZHONG PHARMACEUTICAL FOR THE THREE MONTHS ENDED 31 MARCH 2023

On 26 April 2023, Jiangzhong Pharmaceutical released its quarterly report for the three months ended 31 March 2023.

Jiangzhong Pharmaceutical Co., Ltd. (江中藥業股份有限公司) ("Jiangzhong Pharmaceutical") is a company incorporated in the People's Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is owned as to approximately 43.06% equity interest by China Resources Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (華潤江中製藥集團有限責任公司). The Group controls an effective interest of approximately 22.11% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company.

On 26 April 2023, Jiangzhong Pharmaceutical released its quarterly report for the three months ended 31 March 2023 (the "**Jiangzhong Pharmaceutical Unaudited Financials**"). In which, it announced that the net profit for the three months ended 31 March 2023 was RMB258,015,564.03, representing an increase of 33.28% as compared to the net profit of RMB193,596,007.27 for the same period last year.

Set out below are the key financial information of the Jiangzhong Pharmaceutical Unaudited Financials:

	For the three months ended 31 March	
	2023	2022
	(RMB)	(RMB)
	(unaudited)	(unaudited)
Revenue	1,316,378,726.66	930,726,704.79
Net profit	258,015,564.03	193,596,007.27
Net (decrease)/increase in cash and		
cash equivalents	-57,558,969.30	164,550,538.70
Cash and cash equivalents at the end of		
the period	492,765,197.35	353,159,037.55
	As of	As of
	31 March 2023	31 December 2022
	(RMB)	(RMB)
	(unaudited)	(audited)
Total assets	6,316,949,481.06	6,243,659,088.84
Total liabilities	1,561,109,382.72	1,748,281,711.63
Owner's equity	4,755,840,098.34	4,495,377,377.21

The Jiangzhong Pharmaceutical Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information is limited to Jiangzhong Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.

For further details of the Jiangzhong Pharmaceutical Unaudited Financials, please refer to the quarterly report for the three months ended 31 March 2023 published by Jiangzhong Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

## By order of the Board China Resources Pharmaceutical Group Limited Han Yuewei

Chairman

Hefei, 27 April 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.